Browse the evidence

A 6-week static stretching program, regardless of frequency (1x or 3x per week) or volume-equated duration, does not increase muscle strength or muscle architecture (thickness/pennation angle) of the medial gastrocnemius in healthy, non-athletic males.

If you are doing static stretching to build muscle or get stronger, this 6-week protocol will not work. Whether you stretch once a week for 6 minutes or three times a week for 2 minutes, you will not see changes in muscle size or strength. Stretching is useful for range of motion, but do not expect it to replace resistance training for hypertrophy or strength gains.

Inclusion of genetic risk information in personalized nutrition advice does not significantly improve dietary changes, lifestyle behaviors, or weight loss outcomes compared to generic advice.

Do not pay for expensive genetic testing to guide your diet. Large studies show that knowing your genetic risk for obesity or diabetes does not help you lose weight or eat better than standard healthy eating advice. Focus on proven behavioral strategies like tracking intake and physical activity instead.

Epigenetic modifications (DNA methylation) associated with obesity and diet are largely consequences of the phenotype or acute events rather than causal factors.

Do not pay for 'biological age' tests based on DNA methylation. These changes are often just markers of your current health status, not something you can easily 'fix' with a specific supplement or diet. Focus on proven healthy habits.

Telehealth-delivered dietary interventions for chronic disease management are frequently reported with insufficient detail, preventing accurate interpretation of trial results and implementation in clinical practice.

If you are a clinician looking to implement a telehealth dietary program based on a research paper, do not assume the published description is sufficient. You must actively seek out the full protocol, supplementary materials, or contact the authors directly, as most publications omit critical details about materials, tailoring, and fidelity.

The Core Obesity Model (COM) accurately predicts obesity-related event rates for type 2 diabetes, cardiovascular disease, and obstructive sleep apnea when validated against studies used for its development.

For decision-makers using the Core Obesity Model, the dependent validation results provide high confidence that the model accurately predicts the rates of T2D, CVD, and OSA for populations similar to those used in its development. This supports the use of the model for cost-effectiveness analyses in these specific contexts.

The Core Obesity Model tends to underestimate the incidence of cardiovascular disease, mortality, and type 2 diabetes when validated against independent studies not used in its development.

When using the Core Obesity Model for independent validation, be aware that it tends to underestimate the rates of CVD, mortality, and T2D. This underestimation is particularly pronounced for mortality and stroke. However, the model still shows good linear correlation, and the underestimation may not significantly impact incremental cost-effectiveness ratios if it affects both intervention and comparator arms similarly.

Elevated GDF15 plasma levels are not a causal factor in cardiometabolic diseases such as obesity, type 2 diabetes, or cardiovascular disease, but rather serve as a biomarker of metabolic stress.

Do not rely on GDF15 levels to predict or treat obesity directly. While high GDF15 is a strong warning sign for heart disease and mortality, increasing it artificially (as done in animal studies) does not appear to cause weight loss in humans. Focus on established metabolic health markers instead.

Higher Body Mass Index (BMI) causally increases GDF15 plasma levels, identifying BMI as a driver of GDF15 elevation rather than the reverse.

High GDF15 is a consequence of higher body weight, not the cause. Managing BMI is the primary lever; GDF15 levels will naturally decrease as metabolic stress is reduced.

Longer leukocyte telomere length (LTL) is associated with a significantly lower risk of all-cause mortality and coronary heart disease (CHD) mortality in elderly adults.

Leukocyte telomere length is a biomarker of biological aging and cardiovascular health. This study shows that longer telomeres are associated with lower mortality risk. While you cannot directly 'take' telomere length, maintaining a healthy lifestyle (not smoking, moderate alcohol, healthy diet) is associated with longer telomeres and lower mortality risk. Focus on these modifiable factors rather than trying to directly manipulate telomere length.

Obeticholic acid (25 mg/day) improves liver fibrosis in patients with MASH and stage 2-3 fibrosis, but does not significantly resolve MASH activity compared to placebo.

Obeticholic acid (25 mg daily) can significantly improve liver scarring (fibrosis) in patients with advanced MASH, but it does not reliably eliminate the inflammation (MASH) itself. The main barrier is itching (pruritus). This treatment is for specific high-risk patients, not general MASLD.

Pioglitazone (PPAR-gamma agonist) resolves MASH and reduces fibrosis stage, but its use is limited by adverse effects including fluid retention, weight gain, and osteopenia.

Pioglitazone can resolve MASH and reduce liver scarring, but it causes weight gain and fluid retention, which can worsen heart failure risk. It is generally limited by these side effects, particularly in older women due to fracture risk.

Five days of bed rest does not significantly alter skeletal muscle mitochondrial protein content, enzyme activity, or dynamics (fission/fusion/biogenesis/mitophagy markers) in healthy older adults.

For older adults facing short hospital stays (around 5 days), do not panic about losing metabolic health or mitochondrial density. While muscle mass may decrease, the cellular machinery for energy production remains largely intact during this specific timeframe, suggesting that immediate post-discharge recovery of metabolic function is feasible without needing to rebuild mitochondrial content from scratch.

GIP receptor antagonism, specifically via the peptide GIP(3-30)NH2, increases GIP receptor surface expression and prevents internalization, thereby resensitizing the receptor for subsequent activation by endogenous or exogenous agonists.

Blocking the GIP receptor with specific antagonists like GIP(3-30)NH2 doesn't just turn off the signal; it keeps the receptors on the cell surface ready to receive signals. This resensitization may help overcome the impaired GIP response often seen in type 2 diabetes and obesity, potentially enhancing the effects of other treatments like GLP-1 agonists.

Nutrient-based front-of-pack labeling systems (like Health Star Rating) can assign high health scores to ultra-processed foods, creating a 'health halo' that misleads consumers about the nutritional quality of convenience foods, sports/diet foods, and meat alternatives.

When evaluating packaged foods, do not rely solely on front-of-pack labels like the Health Star Rating. These systems focus on nutrients (sugar, sodium, fiber) but ignore how processed the food is. Look for the ingredient list: if it contains industrial additives, emulsifiers, or protein isolates, it is likely ultra-processed, even if it has a high health score. Prioritize whole, minimally processed foods over highly processed ones with 'good' nutrient profiles.

In longitudinal dietary intervention or crossover trials, the ratio of period-to-period standard deviation to day-to-day standard deviation (RP) determines the trade-off between the number of subjects and the number of measurement days required to achieve statistical precision.

When designing a diet study, do not assume a fixed number of days works for everyone. Calculate the 'RP ratio' (period variation vs. daily variation) for your specific population. If subjects are eating freely (high daily variation), you need more measurement days to get accurate averages, whereas controlled feeding allows fewer days. The biggest precision gains come from the first few days of measurement.

Metformin does not improve insulin-stimulated glucose uptake (insulin sensitivity) in individuals with type 2 diabetes; its primary mechanism is the suppression of lipolysis and reduction of free fatty acids, which enhances basal glucose clearance.

If you are taking metformin, do not expect it to 'fix' your insulin resistance in the sense of making your muscles more efficient at using insulin. Instead, it works by reducing the fat acids in your blood, which helps your body manage blood sugar at rest. This distinction is important for understanding why your insulin levels might drop without a corresponding change in how your muscles respond to high insulin levels.

Waist circumference does not predict insulin resistance better than body mass index (BMI); both measures are similarly correlated with insulin resistance.

You do not need to obsess over your waist circumference as a superior health metric. Your BMI is just as good at predicting your risk for insulin resistance. Focus on maintaining a healthy weight overall rather than trying to optimize one specific body measurement.

Higher body mass index (BMI) is associated with increased striatal dopamine tone in humans, as indicated by the differential displacement of low-affinity PET tracers ([11C]raclopride) compared to high-affinity tracers ([18F]fallypride).

This research suggests that higher body weight is linked to higher baseline (tonic) dopamine levels in the brain's reward centers, which may blunt the response to specific rewards. While this paper does not offer a direct intervention, it implies that weight loss might normalize dopamine tone, potentially improving reward sensitivity. However, the causal direction (does weight cause high dopamine or vice versa?) remains unproven in this cross-sectional study.

Intensive glucose control provides minor cardiovascular benefits compared to lipid-lowering and anti-hypertensive therapies, and targeting very low glycemia may increase mortality risk in certain subgroups.

Do not rely solely on lowering your blood sugar to protect your heart. Managing your blood pressure and cholesterol levels, along with quitting smoking, offers significantly greater protection against cardiovascular disease than intensive glucose control alone. Discuss individualized HbA1c targets with your doctor, as overly aggressive lowering may be harmful for some.

Intensive lifestyle interventions (weight loss) do not significantly reduce cardiovascular event rates in Type 2 Diabetes patients who already have well-controlled baseline cardiovascular risk factors.

If you have Type 2 Diabetes and your blood pressure and cholesterol are already well-managed, intensive weight loss may not further reduce your risk of heart attacks or strokes. However, weight loss remains valuable for improving your quality of life and managing diabetes symptoms. Focus on maintaining your current risk factor control.

Antioxidant supplementation (specifically Vitamin C and E) can attenuate exercise-induced adaptations, such as mitochondrial biogenesis and improvements in VO2max, by interfering with reactive oxygen species (ROS) signaling pathways.

Be cautious with high-dose antioxidant supplements (like Vitamin C and E) if you are training for endurance. They might blunt the fitness gains you are working for by interfering with your body's natural signaling. It is likely better to get antioxidants from food sources rather than high-dose supplements during training blocks.

In women with suspected ischemia, a history of intentional weight cycling (defined as losing ≥10 lbs at least three times) is associated with a significantly lower rate of adverse cardiovascular outcomes compared to non-cyclers, despite having lower HDL-cholesterol levels.

For women with suspected heart issues, attempting to lose weight—even if they regain it and cycle multiple times—does not appear to increase their risk of heart attacks, stroke, or heart failure. In fact, these women had better outcomes than those who never tried to lose weight. This suggests that the intention and effort to manage weight may be beneficial, countering the fear that 'yo-yo' dieting is harmful.

Standard long-term weight management RCTs for severe obesity (BMI ≥35 kg/m2) systematically exclude or underrepresent underserved groups (low SES, racial minorities, mental health conditions), rendering the evidence base non-generalizable to the populations most at risk of severe obesity.

Current weight management guidelines for severe obesity are largely based on research that excludes the people who need them most (those with lower income, mental health issues, or minority backgrounds). If you belong to an underserved group, standard advice may not work for you because it wasn't tested on people like you. Seek programs that explicitly adapt to your cultural, socioeconomic, and logistical needs, rather than assuming standard protocols will be effective.

Handgrip strength reference values for European adults aged 50+ vary significantly by age, sex, and geographic region, with Northern and Western Europe showing higher absolute strength than Southern and Central/Eastern Europe, and standing position yielding higher values than sitting.

If you are over 50, do not compare your handgrip strength to a generic global average. Use the specific reference values for your age group, sex, and European region (Northern, Western, Southern, or Central/Eastern) to accurately assess your muscle health. Standing grip is typically higher than sitting; ensure you are comparing like with like.